The US Bankruptcy Court approved the first amended plan of liquidation and revised disclosure statement of Argos Therapeutics, Inc. on September 24, 2019. The debtor has filed its amended plan in the Court on August 30, 2019. As per the amended plan, Administrative Claims, Priority Tax Claims, Professional Fee Claims, are paid in full in cash. General Unsecured Claims of $19.04 million are recovered 27% i.e. $5.14 million and are settled in cash. Interests shall be canceled, released, and extinguished as of the effective date. The plan will be funded through cash in hand and sale of assets.